BOIVF yields 1.64% · JNJ yields 2.13%● Live data
📍 BOIVF pulled ahead of the other in Year 1
Combined, BOIVF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BOIVF + JNJ for your $10,000?
Bolloré SE engages in the transportation and logistics, communications, and electricity storage solutions businesses in Asia, Africa, the Americas, the Asia-Pacific, and internationally. It operates through Transportation and Logistics, Oil Logistics, Communications, and Electricity Storage and Systems segments. The company offers freight forwarding, railroad, and port services; and distributes and warehouses oil products. It also provides advertising, and communication consulting services; owns and publishes Cnews, a French daily newspaper; provides ticketing and venue services; acts as a pay-TV operator; and operates Mac-Mahon cinema theaters. Further, it develops batteries based on Lithium Metal Polymer technology for use in electric buses, as well as in stationary applications; energy storage solutions; and plastic films for capacitors, and shrink-wrap packaging films, as well as offers Bluebus electric buses. Additionally, the company designs, products, and markets solutions for passenger air and rail transport networks; integrates identification, tracking, and mobility solutions for logistics contractors, industry, and transport; develops terminals, electric charging points, and identification and geolocalization systems; operates shuttles; offers Bluecar electric vehicles and digital transformation solutions; provides equipment to control pedestrian and vehicles; and develops, deploys, and operates point-to-point car sharing solutions. The company was founded in 1822 and is based in Puteaux, France. Bolloré SE is a subsidiary of Financière de l'Odet SE.
Full BOIVF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.